Damage item | Survival IIM patients‡, n = 156, (%) |
---|---|
Muscle severity, VAS | 31(20.0) |
   Muscle atrophy | 7(4.7) |
   Weakness | 53(34.0) |
   Muscle dysfunction | 10(6.7) |
Skeletal severity, VAS, no of test(149)# | 44(29.4) |
   Joint contracture | 1(0.7) |
   Osteopososis with fracture | 4(2.8) |
   Avascular necrosis | 5(3.5) |
   Arthropathy | 9(6.3) |
Cutaneous severity, VAS | 31(20.0) |
   Calcinosis | 7(4.7) |
   Alopecia | 2(1.3) |
   Cutaneous scarring | 15(9.3) |
   Poikiloderma | 20(12.7) |
   Lipodystrophy | 4(2.6) |
Gastrointestinal severity, VAS | 8(5.3) |
   Dysphagia | 8(5.3) |
   Gastrointestinal dysmotility | 1(0.7) |
   Gastrointestinal infarction | 1(0.7) |
Pulmonary severity, VAS | 77(49.3) |
   Dysphonia | 11(7.1) |
   Impaired lung function | 75(48.1) |
   Pulmonary fibrosis | 75(48.1) |
   Pulmonary hypertension | 20(12.8) |
Cardiovascular severity, VAS | 27(17.3) |
   Hypertension | 26(16.7) |
   Ventricular dysfunction | 2(1.3) |
   Angina | 3(1.9) |
   Myocardial infarction | 3(1.9) |
Peripheral vascular severity, VAS | 2(1.3) |
   Tissue pulp loss | 0(0.0) |
   Digit loss | 2(1.3) |
   Thrombosis | 0(0.0) |
   Claudication | 0(0.0) |
Endocrine severity, VAS | 41(26.3) |
   Growth failure | 0(0) |
   Delay in secondary sexual characteristics | 0(0) |
   Hirsutism | 0(0.0) |
   Irregular menses | 2(1.3) |
   Amenorrhea | 0(0.0) |
   Diabetes | 41(26.3) |
   Infertility | NA |
   Sexual dysfunction | NA |
Ocular severity, VAS | 4(2.7) |
   Cataract | 2(1.3) |
   Vision loss | 1(0.6) |
Infection severity, VAS | 4(2.6) |
   Chronic infection | 3(2.0) |
   Multiple infections | 1(0.6) |
Malignancy severity, VAS | 4(2.6) |
   Malignancy | 4(2.6) |
Total damage | Â |
   Total MDI severity of damage > 0†| 112(71.8) |
   Total MDI extent of damage > 0‡ | 115(73.7) |